Drug Interactions between epcoritamab and tofacitinib
This report displays the potential drug interactions for the following 2 drugs:
- epcoritamab
- tofacitinib
Interactions between your drugs
tofacitinib epcoritamab
Applies to: tofacitinib and epcoritamab
Consumer information for this interaction is not currently available.
GENERALLY AVOID: Coadministration of tofacitinib with biologic DMARDs or potent immunosuppressants (e.g., azathioprine, 6-mercaptopurine, cyclosporine, and tacrolimus) may potentiate the risk of infections as well as lymphoma and other malignancies. Serious and sometimes fatal infections due to bacterial, mycobacterial, invasive fungal, viral, or other opportunistic pathogens have been reported in patients receiving tofacitinib, most of whom were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Lymphoma and other malignancies, including melanoma and non-melanoma skin cancers, have also been observed with tofacitinib use. Epstein Barr virus-associated posttransplant lymphoproliferative disorder has been observed at an increased rate in renal transplant patients treated with tofacitinib and concomitant immunosuppressive agents (basiliximab, high-dose corticosteroids, and mycophenolic acid) relative to cyclosporine plus the same induction regimen (2.3% vs. 0%). Data on the use of tofacitinib with all biologic DMARDs and/or immunosuppressants are not available.
MANAGEMENT: Concomitant use of tofacitinib with biologic DMARDs or potent immunosuppressants should generally be avoided. If coadministration is necessary, patients should be closely monitored for the development of signs and symptoms of infection during and after treatment, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy. If a serious infection, an opportunistic infection, or sepsis develops, tofacitinib should be interrupted until the infection is controlled.
Drug and food interactions
No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.